R Squared’s SELLAS Life Sciences SLS Stock Holding History

R Squared’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,197	Closed	-$2.29K	–	1311
2024 Q4	$2.29K	Buy	+2,197	New	+$2.51K	﹤0.01%	1445

Other funds holding SLS

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OCG

Opus Capital Group Cincinnati, Ohio $1.03B AUM 20.67% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

R Squared's SLS Position: Q1 2025 in Review

R Squared sold out of SELLAS Life Sciences (SLS) in Q1 2025, closing a stake of 2,197 shares — an estimated $2.29K sold.

R Squared first reported a position in SLS in Q4 2024 and held it in 1 quarter. The position peaked at $2.29K in Q4 2024. 45 funds tracked by Wall St. Rank hold SLS as of Q1 2025.

R Squared reported no remaining SELLAS Life Sciences position as of Q1 2025 after selling out during the quarter.
R Squared sold 2,197 SELLAS Life Sciences shares in Q1 2025, an estimated $2.29K.
R Squared first reported a position in SELLAS Life Sciences in Q4 2024 and held it in 1 quarter.
R Squared's SELLAS Life Sciences position peaked at $2.29K in Q4 2024.
45 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.